Acute hyperglycemia abolishes cardioprotection by remote ischemic perconditioning

Tamás Baranyai¹, Csilla Terézia Nagy¹, Gábor Koncsos¹, Zsófia Onódi¹, Melinda Károlyi-Szabó¹, András Makkos¹, Zoltán V. Varga¹, Péter Ferdinandy¹²† and Zoltán Giricz¹²*†

Abstract

Background: Remote ischemic perconditioning (RIPerC) has a promising therapeutic insight to improve the prognosis of acute myocardial infarction. Chronic comorbidities such as diabetes are known to interfere with conditioning interventions by modulating cardioprotective signaling pathways, such as e.g., mTOR pathway and autophagy. However, the effect of acute hyperglycemia on RIPerC has not been studied so far. Therefore, here we investigated the effect of acute hyperglycemia on cardioprotection by RIPerC.

Methods: Wistar rats were divided into normoglycemic (NG) and acute hyperglycemic (AHG) groups. Acute hyperglycemia was induced by glucose infusion to maintain a serum glucose concentration of 15–20 mM throughout the experimental protocol. NG rats received mannitol infusion of an equal osmolarity. Both groups were subdivided into an ischemic (Isch) and a RIPerC group. Each group underwent reversible occlusion of the left anterior descending coronary artery (LAD) for 40 min in the presence or absence of acute hyperglycemia. After the 10-min LAD occlusion, RIPerC was induced by 3 cycles of 5-min unilateral femoral artery and vein occlusion and 5-min reperfusion. After 120 min of reperfusion, infarct size was measured by triphenyltetrazolium chloride staining. To study underlying signaling mechanisms, hearts were harvested for immunoblotting after 35 min in both the NG and AHG groups.

Results: Infarct size was significantly reduced by RIPerC in NG, but not in the AHG group (NG + Isch: 46.27 ± 5.31 % vs. NG + RIPerC: 24.65 ± 7.45 %, p < 0.05; AHG + Isch: 54.19 ± 4.07 % vs. 52.76 ± 3.80 %). Acute hyperglycemia per se did not influence infarct size, but significantly increased the incidence and duration of arrhythmias. Acute hyperglycemia activated mechanistic target of rapamycin (mTOR) pathway, as it significantly increased the phosphorylation of mTOR and S6 proteins and the phosphorylation of AKT. In spite of a decreased LC3II/LC3I ratio, other markers of autophagy, such as ATG7, ULK1 phosphorylation, Beclin 1 and SQSTM1/p62, were not modulated by acute hyperglycemia. Furthermore, acute hyperglycemia significantly elevated nitrative stress in the heart (0.87 ± 0.01 vs. 0.50 ± 0.04 µg 3-nitrotyrosine/mg protein, p < 0.05).

Conclusions: This is the first demonstration that acute hyperglycemia deteriorates cardioprotection by RIPerC. The mechanism of this phenomenon may involve an acute hyperglycemia-induced increase in nitrative stress and activation of the mTOR pathway.

Keywords: Remote ischemic conditioning, Ischemia/reperfusion injury, Acute hyperglycemia, Autophagy, Nitrosative stress
Background
Remote ischemic conditioning (RIC) is a clinically applicable cardioprotective intervention induced by intermittent occlusions and reperusions on a remote organ e.g., a limb. It is proved to be highly effective against acute ischemia/reperfusion injury in animal models [1–4]. Due to its accessibility and simplicity, RIC was rapidly translated into different clinical situations of cardiovascular events [1, 3]. Despite the promising results of preceding animal studies, its infarct size reducing potential is equivocal in acute coronary syndrome patients [1]. Moreover, the largest randomized multi-center clinical trial including 1612 patients [Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA)] did not show any benefit on major adverse cardiac and cerebral events [5]. Reasons of these discrepancies are yet to be determined.

It has been shown that comorbidities (e.g., diabetes mellitus, hyperlipidemia) and comedications (e.g., angiotensin-converting enzyme inhibitors, statins) deteriorate cardioprotective effects of various conditioning stimuli (e.g., ischemic preconditioning and postconditioning) [2, 6, 7], however, only a few papers examined these chronic confounding factors in RIC so far. For example, Kiss et al. showed that remote ischemic preconditioning, i.e., RIC applied during a prolonged myocardial ischemia, (RIPerC) is not effective in a rat model of type 1 diabetes mellitus [8]. Similarly, the cardioprotective effect of RIC has been shown to be deteriorated in patients with type 1 and 2 diabetes mellitus [9]. Apart from being a major component of chronic metabolic diseases, hyperglycemia may also occur in acute situations (e.g., sympathetic over-activation during acute coronary syndrome) [10]. Hyperglycemia in nondiabetic patients (where hyperglycemia is unlikely to persist) is generally associated with adverse outcomes after an acute myocardial infarction [11]. It is not known whether this acute hyperglycemia is the cause of adverse outcomes or it only reflects the severity of the acute myocardial infarction [10]. Furthermore, it has been shown that hyperglycemia inhibits cardioprotection conferred by ischemic preconditioning or cardio-protection by various pharmacological agents [12–14]. However, it is not known whether acute hyperglycemia without pre-existing impaired glucose metabolism hinders cardioprotection by RIPerC.

Therefore, we aimed to investigate whether RIPerC-induced cardioprotection is affected by acute hyperglycemia and demonstrated for the first time in the literature that RIPerC failed to exert cardioprotection in acute hyperglycemia without pre-existing systemic metabolic disturbance. Furthermore, we have also shown that acute hyperglycemia increased nitrative stress and activated cardiac mechanistic target of rapamycin (mTOR) pathway, but not cardiac autophagy, which might be involved in the mechanism of the lost cardioprotection by RIPerC in acute hyperglycemia.

Methods
This investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85–23, revised 1996), to the EU Directive (2010/63/EU) and was approved by the animal ethics committee of the Semmelweis University, Budapest, Hungary.

In vivo experiments (Fig. 1)
220–280 g male Wistar rats were anaesthetized with 60 mg/kg pentobarbital. Since autophagy and cardioprotection are markedly influenced by fasting [15–17], animals were not fasted before enrolment. The absence of pedal reflex was considered as deep surgical anaesthesia. Electric activity of the heart was monitored (AD Instruments, Bella Vista, Australia). Body temperature was maintained with a heat pad at physiological temperature (35.8–38.3 °C). Rats were ventilated with 10 mL/kg stroke volume at rate of 80 strokes/min (Ugo-Basile, Gemonio, Italy).

Rats were randomized into 2 groups: control normoglycemic (NG), and acute hyperglycemic (AHG). AHG animals received 50 % dextrose (vWR, Radnor, PA, US) infusion via tail vein from the start of the experimental protocol. A blood glucose level of 15–20 mM was reached within 5 min by an infusion rate of 150 µL/min. Then infusion rate was adjusted to maintain blood glucose levels between 15 and 20 mM throughout the entire protocol (0–60 µL/min, with an average of 50 µL/min), which was measured every 15 min (Accu-Check, Roche, Basel, Switzerland). In NG animals, an equal osmolarity, 46 % mannitol solution was administered (vWR, Radnor, PA, US, induction rate: 150 µL/min for 5 min, then 50 µL/min).

After 35 min of in vivo perfusion, half of the animals from normoglycemic and acute hyperglycemic groups were sacrificed, and hearts were excised, immersed readily in ice-cold Krebs-Henseleit solution until they were mounted. They were then perfused in Langendorff mode for 1 min with oxygenated (95 % oxygen/5 % CO2 gas mixture) Krebs-Henseleit solution (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.25 mM CaCl2, 1.2 mM KH2PO4, 25 mM NaHCO3 and 11 mM glucose) at 37 °C to wash out blood, as described earlier [18]. Then the hearts were snap-frozen in liquid nitrogen and stored at −80 °C until further experiments. The other half of the animals were further randomized into four groups:
(1) control ischemic with normoglycemia (NG + Isch), (2) remote ischemic perconditioned with NG (NG + RIPerC), (3) ischemic with acute hyperglycemia (AHG + Isch), and (4) remote ischemic perconditioned with acute hyperglycemia (AHG + RIPerC). At 35′ of the study protocol, left anterior descending coronary artery (LAD) was occluded with a 6–0 polypropylene suture via median thoracotomy for 40 min. Occlusion was confirmed by ST segment elevation, arrhythmias and paling of the occluded area. RIPerC was induced by 3 cycles of 5 min occlusion and 5 min reperfusion of the right femoral vessels starting after 10 min of the LAD occlusion. Both the femoral artery and vein were occluded with a metal vessel clamp after isolation of the vessels from the surrounding connective tissue and femoral nerve. At the end of the 40 min index ischemia, reperfusion was induced by loosening the suture. At the end of the 120 min reperfusion, hearts were harvested for infarct size evaluation.

Infarct size measurement
Hearts were excised after 120 min of reperfusion, perfused for 1 min with oxygenated Krebs-Henseleit solution in Langendorff mode. LAD was reoccluded, and the area at risk was negatively stained with Evans blue. For the assessment of viable myocardial tissue, 2 mm thick slices were cut and incubated in 1 % triphenyltetrazolium chloride (Sigma, St. Louis, MO, US) at 37 °C for 15 min. Slices were fixed in 4 % formalin for 16 h, weighed and scanned. Planimetric analyses were performed by two independent investigators with InfarctSize 2.4b software (Pharmahungary Group, Budapest, Hungary). Area at risk was expressed as the proportion of the left ventricular mass, and infarct size as the proportion of the area at risk mass.

Arrhythmia analysis
An electrocardiogram was recorded throughout the entire experiment. Arrhythmia analysis was performed according to the Lambeth conventions, and arrhythmia incidence and duration scores were calculated [19].

Myocardial 3-nitrotyrosine measurement
Free myocardial 3-nitrotyrosine was measured from left ventricular samples harvested at 35′ with 3-nitrotyrosine ELISA (Cayman, Ann Arbor, MI, US) according to the manufacturer’s protocol.

Western blot
Left ventricular tissue was homogenized in radioimmunoprecipitation assay buffer (Cell Signaling, Danvers, MA, US) supplemented with protease inhibitor (Roche, Basel, Switzerland), sodium fluoride (Sigma, St. Louis, MO, US) and PMSF (Sigma, St. Louis, MO, US). Protein concentration of the homogenates was measured by Bicinchoninic Acid Assay kit (Thermo Fisher Scientific, Waltham, MA, US). Equal amount of protein (25 µg) was mixed with reducing 5× Laemml buffer, loaded and separated in a 4–20 % precast Tris–glycine SDS polyacrilamide gel (Bio-Rad, Hercules, CA, US) at 350 mA for 2 h. Proper transfer was visualized with Ponceau staining (Sigma, St. Louis, MO, US). Membranes were blocked with 5 % BSA (Santa Cruz Biotechnology, Dallas, TX, US) in Tris-buffered saline containing 0.05 % Tween-20 (0.05 % TBS-T; Sigma, St. Louis, MO, US) at room temperature for 2 h. Membranes were probed with primary antibodies purchased from Cell Signaling (Danvers, MA, US) overnight at 4 °C (markers of mTOR pathway and its upstream modulators: phospho-mTOR [Ser2448]—#2971; mTOR—#2972;
phospho-S6 [Ser235/236]—#2211; ribosomal S6—#2317; phospho-AKT [Ser473]—#9271; AKT—#9272; phospho-AMP-activated protein kinase α [AMPKa; Thr172]—#2535; AMPKa—#5831; phospho-extracellular signal-regulated kinase 1/2 [Erk1/2; Thr202/Tyr204]—#9106; Erk1/2—#9107; well-established markers of autophagy: microtubule-associated protein 1 light chain 3 A/B [LC3A/B]—#4108; beclin-1—#3495; SQSTM1/p62—#5114; phospho-UNC-51-like kinase 1 [p-ULK1; Ser555]—#5869; ULK1—#4773; autophagy-related gene 7 [ATG7]—#8558; Bcl-2/E1B-interacting protein 3 [BNIP3]—#3769; loading control: GAPDH—#5174), and with corresponding horseradish peroxidase-conjugated secondary antibodies (Cell Signaling, Danvers, MA, US) by Chemidoc XRS+ an enhanced chemiluminescence kit (Bio-Rad, Hercules, CA, US) by Chemidoc XRS. Antibodies detecting phosphorylated epitopes were removed with Pierce Stripping Buffer (Thermo Fisher Scientific, Waltham, MA, US) before incubation with antibodies detecting the total protein.

**Triton X-100-insoluble SQSTM1/p62 Western blot**

Left ventricular tissue was homogenized with Tissue-Lyser (Qiagen, Venlo, Netherlands) in a homogenation buffer containing 50 mM Tris, 150 mM NaCl, 1 mM EDTA, 10 % glyceral and 2 % Triton X-100 (pH 8.0) supplemented with protease inhibitor (Roche, Basel, Switzerland), sodium fluoride (Sigma, St. Louis, MO, US) and PMSF (Sigma, St. Louis, MO, US). Homogenates were centrifuged (10,000 × g, 10 min, 4 °C) supernatant was carefully removed and discarded. Pellet was washed with the abovementioned homogenation buffer once again (10,000 × g, 10 min, 4 °C). Then pellets were resuspended in sample buffer containing 62.5 mM Tris–HCl, 5 % glyceral and 1.3 % SDS. Protein concentration of the homogenates was measured by Bicinchoninic Acid Assay kit (Thermo Fisher Scientific, Waltham, MA, US). Equal amount of protein (20 µg) was loaded, separated and processed under reducing conditions as described above.

**Statistical analysis**

Data was expressed as mean ± standard error of mean. Student’s t test and two-way ANOVA with LSD as a post hoc test were used for statistical analyses in most cases, Kaplan–Meier estimation for evaluating mortality data, and Kruskal–Wallis analysis for analyzing scores. Statistical significance was accepted if p < 0.05.

**Results**

Acute hyperglycemia abolishes the protective effect of RIPerC

To investigate the effect of acute hyperglycemia on the efficacy of RIPerC, acute hyperglycemia was induced with a 50 % dextrose infusion during in vivo ischemia/reperfusion experiments. Blood glucose level was significantly elevated due to dextrose perfusion in both AHG + Isch and AHG + RIPerC groups compared to the corresponding NG group from at least the 15th min of perfusion [Table 1, preliminary results showed that acute hyperglycemia developed in 5 min (17.2 ± 1.8 mM, n = 4)]. Although baseline blood glucose appears to be higher than reported normal levels, it should be noted that baseline plasma glucose levels were measured in non-fasting animals which might have resulted in this relatively elevated, but still normoglycemic blood glucose level [20]. Elevated blood glucose levels did not influence the heart rate and blood pressure of the rats (Table 2). Until the end of the ischemic period, mortality rate was 11.1 % (1), 9.1 % (1), 30.0 %, (3) and 14.3 % (1), whereas total mortality was 0.0 % (0), 10.0 % (1), 14.3 %, (1) and 16.7 % (1) during reperfusion in Isch, RIPerC, AHG + Isch and AHG + RIPerC groups, respectively. Mortality was not significantly different between groups.

Infarct size was significantly smaller in NG + RIPerC group compared to NG + Isch (24.65 ± 7.45 vs. 46.27 ± 5.31 %; p < 0.05; n = 7–10; Fig. 2), while RIPerC failed to decrease infarct size in AHG + RIPerC group when compared to AHG + Isch (52.76 ± 3.80 vs. 54.19 ± 4.07 %; p > 0.05; n = 5–6; Fig. 2). Furthermore, acute hyperglycemia per se did not aggravate cardiac necrosis (Fig. 2). There was no difference in heart rate and blood pressure of the rats (Table 2).

|  | 0′ | 15′ | 30′ | 70′ | 190′ |
|---|---|---|---|---|---|
| NG | 8.6 ± 0.3 | 6.8 ± 0.2 | 8.4 ± 0.7 | NG + Isch | 92 ± 0.7 |
| AHG | 8.5 ± 0.3 | 17.7 ± 1.0* | 21.3 ± 2.1* | AHG + Isch | 18.0 ± 1.3* |
|  |  |  |  | AHG + RIPerC | 199 ± 1.4* |

NG normoglycemia, AHG acute hyperglycemia, Isch ischemia only group, RIPerC remote ischemic preconditioning

*p < 0.05 vs. corresponding time point of NG + Isch group

*p < 0.05 vs. corresponding time point of NG + RIPerC group. n = 5–10
between the areas at risk of various groups (NG + Isch: 51.58 ± 1.65%; NG + RIPerC: 45.13 ± 2.99%; AHG + Isch: 49.44 ± 3.90; AHG + RIPerC: 43.64 ± 2.25%; p > 0.05; n = 5–10).

**AHG exacerbates the incidence and duration of arrhythmias during ischemia**

Arrhythmia analysis revealed that AHG compared to NG significantly increased the incidence and duration of arrhythmias during the whole myocardial ischemic period, but arrhythmia incidence and duration were not different during reperfusion (Table 3).

RIPerC did not alter arrhythmia scores from the time point it was applied, as compared to Isch group (Table 3). Furthermore, RIPerC did not decrease arrhythmia scores during acute hyperglycemia compared to AHG + RIPerC (Table 3).

**Acute hyperglycemia increases nitrative stress**

Increased oxidative and nitrative stresses are often implicated in the disruption of cardioprotective interventions. Therefore, 3-nitrotyrosine content, a marker of nitrative stress was measured in hearts of NG and AHG rats at 35’.

Cardiac 3-nitrotyrosine was significantly elevated due to acute hyperglycemia (0.87 ± 0.01 vs. 0.50 ± 0.04 μg 3-nitrotyrosine/mg protein; p < 0.05; n = 8; Fig. 3).

**Acute hyperglycemia activates mTOR pathway**

Since the oxidative and nitrative stress have been previously shown to interact with mTOR pathway [21], we evaluated the expression and/or phosphorylation of mTOR pathway associated proteins. The phosphorylation of mTOR (Ser2448) and S6 (Ser235/236) was significantly elevated (Fig. 4a, b), which indicates that the activity of mTOR complex I was increased in AHG group. Phosphorylation of AKT at site Ser473 was also significantly elevated in AHG group (Fig. 4c), however, other mTOR regulators, such as phosphorylated AMPKα (Thr172) and Erk1/2 (Thr202/Tyr204) were unchanged in AHG group as compared to NG (Fig. 4d, e).

**Acute hyperglycemia does not influence autophagy**

Since oxidative/nitrative stress and mTOR pathway have been shown to interact with autophagy, expression and/or phosphorylation of autophagy-related proteins were assessed in NG and AHG groups. LC3II/LC3I ratio was significantly decreased due to acute hyperglycemia (Fig. 5a), however, other autophagy-related proteins such as Beclin-1, total and Triton X-100-insoluble SQSTM1/p62, phospho-ULK1 (Ser555), ATG7 and BNIP3 were unchanged in AHG group (Fig. 5b–g).

**Discussion**

We have demonstrated for the first time in the literature that acute hyperglycemia with no preceding diabetes mellitus abolished the infarct size limiting effect of RIPerC in an in vivo rat model with acute coronary occlusion.
Arrhythmia incidence scores

|                  | 0–35’     | 35–45’    | 45–75’    | 75–195’   |
|------------------|-----------|-----------|-----------|-----------|
| NG               | 4.87 ± 1.28 | 1.79 ± 0.73 | 2.47 ± 0.69 | 8.10 ± 3.01 |
| NG + Isch       |           |           |           |           |
| NG + RIPerC     | 3.09 ± 1.57 | 3.03 ± 0.98 | 6.56 ± 1.12 |           |
| AHG              | 1.99 ± 0.45 | 14.06 ± 3.34* | 23.17 ± 2.1* | 8.79 ± 1.97 |
| AHG + Isch      |           |           |           |           |
| AHG + RIPerC    | 10.69 ± 6.68 | 12.88 ± 6.87* | 7.72 ± 3.19 |           |

Arrhythmia duration scores

|                  | 0–35’     | 35–45’    | 45–75’    | 75–195’   |
|------------------|-----------|-----------|-----------|-----------|
| NG               | 3.65 ± 0.84 | 1.59 ± 0.61 | 2.18 ± 0.57 | 7.58 ± 2.92 |
| NG + Isch       |           |           |           |           |
| NG + RIPerC     | 1.88 ± 0.73 | 2.18 ± 0.06 | 4.98 ± 0.82 |           |
| AHG              | 1.99 ± 0.45 | 7.49 ± 1.58* | 14.46 ± 2.84* | 8.27 ± 1.95 |
| AHG + Isch      |           |           |           |           |
| AHG + RIPerC    | 4.08 ± 1.43 | 8.98 ± 3.62* | 7.71 ± 3.18 |           |

NG normoglycemia, AHG acute hyperglycemia, Isch ischemia only group, RIPerC remote ischemic preconditioning

*p < 0.05 vs. corresponding time point of NG + Isch group

*p < 0.05 vs. corresponding time point of NG + RIPerC group. n = 5–10

The majority of novelty of this study is that experimentally induced acute hyperglycemia with no preceding diabetes diminishes cardioprotective effect of RIPerC. This finding supports previous observations showing that other forms of cardioprotection may be affected by acute hyperglycemia. Kersten et al. described that cardioprotection by ischemic preconditioning is absent during acute hyperglycemia in dogs [13]. Similarly, acute hyperglycemia diminished cardioprotection conferred by isoflurane-induced preconditioning, however, it was reversible by increasing the minimum alveolar concentration in dogs [12]. It has been recently shown that hyperglycemia at admission does not deteriorate RIPerC, however, in this patient cohort, the presence of comorbidities, such as treated or untreated diabetes, have not been reported [22]. Although we showed here that acute hyperglycemia did not influence the extent of myocardial infarct size, a few studies have reported that acute hyperglycemia without any pre-existing pathophysiological conditions aggravate myocardial infarct size [13, 23, 24]. However, the majority of publications concludes that acute hyperglycemia per se do not change infarct size [25–27]. The seemingly contradictory findings may have been the result of applying different glucose concentrations, since reports suggesting harmful effects of acute hyperglycemia applied consistently higher glucose concentrations (i.e., over 30 mM).

The underlying mechanism of the loss of RIPerC-induced cardioprotection by acute hyperglycemia is not fully understood. Increased oxidative and nitrative stresses are implicated in the disruption of cardioprotective interventions by metabolic co-morbidities [2, 28–32], while conditioning stimuli such as RIC alleviates nitrative stress [28]. It was shown here that nitrative stress was also increased in acute hyperglycemia in rat heart in vivo, and similar results have been shown in isolated rat hearts perfused with hyperglycemic solution [33]. These findings clearly signal the pivotal role of excessive nitrative stress in the loss of cardioprotection in disturbed glucose homeostasis.

Oxidative and nitrative stresses have also been shown to directly disrupt autophagy (see for review: [34]). Therefore, we assessed cardiac autophagy and its regulatory pathways in acute hyperglycemia. However, we found that autophagy was unlikely to be disrupted, as only LC3II/LC3I ratio was significantly reduced, but other autophagy-related parameters were not. Although cardiac autophagy was not modulated, its most important regulator the mTOR pathway was largely activated by acute hyperglycemia. Since it has been shown that the inhibition of mTOR by rapamycin elicits cardioprotective effect in vivo [35, 36], and that RIC, while protecting the myocardium against ischemia, downregulates mTOR [37]. We hypothesize that the upregulated mTOR pathway might be responsible for this loss of cardioprotection...
by RIPerC in acute hyperglycemia. Furthermore, it was also been previously shown that under nutrient excess and oxidative stress, such as that seen in hyperglycemia, the mTOR pathway and its upstream modulator AKT are increasingly activated [38–40]. It is well established that activation of AKT upon reperfusion plays a central role in the mediation of cardioprotection conferred by ischemic pre-, post-, and remote conditioning (see for review: [41]). However, the cardioprotective effect of AKT activation before cardiac ischemia is controversial. Although genetic activation of AKT (24 h or 48 h prior to ischemia) protected the heart from ischemic insults [42, 43], more acute activation of AKT by SC79 and chronic AKT activation in ob/ob mice prior to ischemia did not confer protection against ischemia/reperfusion injury [44, 45]. We also demonstrated here that acute hyperglycemia-induced AKT activation prior to myocardial ischemia did not alter infarct size. These discrepancies could be explained by the fact that genetic activation of AKT induces an overwhelming alteration in cardiac gene expression profile [46] which might have not yet developed in our acute experiments. Moreover, we also showed that despite the acute hyperglycemia-induced activation of AKT, cardioprotective effects of remote ischemic perconditioning are lost. Similarly, it was previously reported that AKT activation prior to ischemia significantly interferes with protective stimuli, such as ischemic pre- and postconditioning [45, 47]. Therefore, one may conclude that the timing and the method of activation of AKT can profoundly influence its role in cardioprotection. Furthermore, AKT has a central role in the insulin signalling cascade and in the modulation of the mTOR pathway [48]. Here we evidenced an increased AKT in acute hyperglycemia, however, others found opposing trends in various cellular and in vivo models of hyperglycemia [26, 49, 50]. This discrepancy might be attributed to the substantial difference in the activation state of insulin signalling between model systems (i.e., missing insulin in STZ-treated animals or limited supply of insulin in cell cultures). Nevertheless, our current results demonstrate that AKT activation in an in vivo model with intact insulin and glucose homeostasis is detrimental on cardioprotection.

Limitations
Here we evaluated the effect of acute hyperglycemia on the myocardium without ischemia or RIPerC. It is well established that ischemia and cardioprotective...
interventions significantly and dynamically influence autophagy and nitrative stress [28, 51, 52]. Thus, if such parameters are assessed after ischemia, i.e., in cardiac tissues with different level of exposure to ischemic insult, corresponding ischemic, border and remote zones, it would be unclear whether a possibly deteriorated autophagy and increased nitrative stress are causes or consequences of ischemia and/or reperfusion injury. Nevertheless, such experiments are still warranted to clarify the role of the mTOR pathway, autophagy and nitrative stress in the loss of RIPerC in acute hyperglycemia.

Conclusions
In conclusion, here we have shown evidence for the first time in the literature that the cardioprotective effect of RIPerC is lost in acute hyperglycemia. The mechanism of this phenomenon may involve an acute hyperglycemia-induced increase of nitrative stress and activation of the AKT-mTOR pathway, but not the disruption of cardiac autophagy. This data suggests that the efficacy of RIPerC might be compromised in clinical settings with acute hyperglycemia.

Authors’ contributions
TB designed the study, performed in vivo studies, interpreted data and drafted the manuscript. CTN performed in vivo studies. GK performed 3-nitrotyrosine ELISA. ZO and AM performed infarct size and ECG analyses. MKS performed Western blots. ZVV, PF and ZG designed the study, interpreted data and revised manuscript. All authors read and approved the final manuscript.

Author details
1 Cardiometabolic Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Nagyvárad tér 4, Budapest 1089, Hungary. 2 Pharmahungary Group, Szeged, Hungary.

Acknowledgements and funding sources
This study was supported by the Hungarian Scientific Research Fund (OTKA K 109737, OTKA PD 109051). ZG holds a “János Bolyai Fellowship” from the Hungarian Academy of Sciences and ZVV is supported by the National Program of Excellence (TÁMOP 4.2.4.A/1-11-1-2012-0001). OZ and AM are medical students supported by the Student’s Scientific Association of the Semmelweis University. We are greatly indebted to Craig István Hausler for language editing the manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 15 August 2015 Accepted: 11 November 2015 Published online: 18 November 2015

References
1. Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. J Am Coll Cardiol. 2015;65(2):177–95. doi:10.1016/j.jacc.2014.10.031.
2. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comediations with ischemia/reperfusion
injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014;66(4):1142–74. doi:10.1124/pr.113.008300.

3. Gaspar A, Leite-Moreira AF. Remote cardiac ischemic conditioning: underlying mechanisms and clinical applications. Revista portuguesa de cirurgia cardio-toracica e vascular: orgao oficial da Sociedade Portuguesa de Cirurgia Cardio-Toracica e Vasc. 2012;19(4):183–90.

4. Xu J, Sun S, Lu X, Hu X, Yang M, Tang W. Remote ischemic pre- and postconditioning improve postresuscitation myocardial and cerebral function in a rat model of cardiac arrest and resuscitation. Crit Care Med. 2015;43(1):e1–8. doi:10.1097/CCM.0000000000000684.

5. Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, et al. Remote ischemic preconditioning and outcomes of cardiac surgery. New Engl J Med. 2015;373(5):1408–17. doi:10.1056/NEJMoa1413534.

6. Salie R, Huisamen B, Lochner A. High carbohydrate and high fat diets protect the heart against ischaemia-reperfusion injury. Cardiovasc Diabetol. 2014;13:109. doi:10.1186/1475-2840-13-109.

7. Hauseney-DJ, Whittington H, Wynne AM, Begum SS, Theodorou L, Riksen N, et al. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc Diabetol. 2013;12:154. doi:10.1186/1475-2801-12-154.

8. Kiss A, Tratsiakovich Y, Gonon AT, Fedotovskaya O, Lanner JT, Andersson DB, et al. Effect of remote ischemic preconditioning in the elderly patients with coronary artery disease with diabetes mellitus undergoing elective drug-eluting stent implantation. Angiology. 2014;65(5):660–6. doi:10.1177/0003315514539067.

9. Wei CH, Litwin SE. Hyperglycemia and adverse outcomes in acute myocardial infarction. Anesthesiology. 2002;96(1):183–8.

10. Wei CH, Litwin SE. Hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol. 2006;290(9):H2752–75. doi:10.1152/ajpheart.01242.2010.

11. Timmer JR, Hoekstra M, Nijsten MW, van der Horst IC, Ottervanger JP, Slagerland R, et al. Pharmacological implications in obesity and metabolic syndrome. Circulation. 2014;130(5):e1–13. doi:10.1161/CIR.0b013e3182aa1c31.

12. Ciriello A, Quagliaro L, D’Amico M, Filippo C, Marfella R, Nappi F, et al. Remote ischemic preconditioning with–but not without–metabolic support protects the neonatal porcine heart against ischemia-reperfusion injury. Int J Cardiol. 2014;170(3):388–93. doi:10.1016/j.ijcard.2013.11.020.

13. Connelly JH, Barba I, Inserte J, Miro-Casas E, Ruiz-Meana M, W, Herijgers P. Angiotensin-converting enzyme inhibition and food intake: underlying mechanisms and clinical applications. Revista portuguesa de Cirurgia Cardio-Toracica e Vasc. 2012;19(4):183–90.

14. Clarke SJ, McCormick LM, Dutka DP. Optimising cardioprotection under the influence of circadian clocks: the role of matrix metalloproteinase-2 inhibition. J Pharmacol Exp Ther. 2006;316(1):154–61. doi:10.1124/jpet.105.091140.

15. Gottlieb RA, Finley KD, Mentzer JR. Cardioprotection requires taking out the trash. Basic Res Cardiol. 2009;104(4):169–80. doi:10.1007/s00395-009-0019-9.

16. Godar RJ, Ma X, Liu H, Murphy JT, Weimer CJ, Kolvekar S, et al. Remote ischemic preconditioning the myocardium to ischemia-reperfusion injury. Autophagy. 2005;1(9):1357–60. doi:10.1588/15548627.2015.1063768.

17. Van der Meer N, Gnevelstein I, Vanderplas A, Oosterlinck W, Flameng W, Herijgers P. Autophagy-lysosome machinery by intermittent fasting preconditioning the myocardium to ischemia-reperfusion injury. Autophagy. 2015;11(9):1537–60. doi:10.1080/15548627.2015.1063768.

18. Van der Meer N, Gnevelstein I, Vanderplas A, Oosterlinck W, Flameng W, Herijgers P. Autophagy-lysosome machinery by intermittent fasting preconditioning the myocardium to ischemia-reperfusion injury. Autophagy. 2015;11(9):1537–60. doi:10.1080/15548627.2015.1063768.

19. Curtis MJ, Walker MJ. Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischemia. Cardiovasc Res. 1988;20(6):665–65.

20. Matsuo T, Izuomot K. Effects of dietary D-psicose on diurnal variation in plasma glucose and insulin concentrations of rats. Biosci Biotechnol Biochem. 2006;70(9):2081–5.

21. Sciarretta S, Volpe M, Sadoshima J. Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ Res. 2014;114(3):549–64. doi:10.1161/CIRCRESAHA.114.302022.

22. Slotto AD, Schmidt MR, Munk K, Schmidt M, Pedersen L, Sorensen HT, et al. Impact of cardiovascular risk factors and medication use on the efficacy of ischemic preconditioning: post hoc subgroup analysis of a randomised controlled trial. BMJ Open. 2015;5(4):e006923. doi:10.1136/bmjopen-2014-006923.

23. Mapanga RF, Joseph D, Symington B, Garson KL, Kimar C, Kelly-Laubscher A, et al. Dinitrophenol effects of acute hyperglycemia on the rat heart. Acta Physiol. 2014;210(3):546–64. doi:10.1111/apha.12184.
cytotoxicity by activation of the AMPK/mTOR signal pathway in H9c2 cells. Mol Cell Biochem. 2014;389(1–2):249–56. doi:10.1007/s11010-013-1946-6.

40. Yeshao W, Gu J, Peng X, Nairn AC, Nadler JL. Elevated glucose activates protein synthesis in cultured cardiac myocytes. Metab Clin Exp. 2005;54(11):1453–60. doi:10.1016/j.metabol.2005.05.010.

41. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res. 2015;116(4):674–99. doi:10.1161/CIRCRESAHA.116.305348.

42. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000;101(6):660–7.

43. Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 2001;104(3):330–5.

44. Moreira JB, Wohlwend M, Alves MN, Wisloff U, Bye A. A small molecule activator of AKT does not reduce ischemic injury of the rat heart. J Transl Med. 2015;13:76. doi:10.1186/s12967-015-0444-x.

45. Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol. 2008;295(4):H1580–6. doi:10.1152/ajpheart.00379.2008.

46. Cook SA, Matsui T, Li L, Rosenzweig A. Transcriptional effects of chronic Akt activation in the heart. J Biol Chem. 2002;277(25):22528–33. doi:10.1074/jbc.M201462200.

47. Fullmer TM, Pei S, Zhu Y, Sloan C, Manzanares R, Henrie B, et al. Insulin suppresses ischemic preconditioning-mediated cardioprotection through Akt-dependent mechanisms. J Mol Cell Cardiol. 2013;64:20–9. doi:10.1016/j.yjmcc.2013.08.005.

48. Dibble CC, Cantley LC. Regulation of mTORC1 by PI3 K signaling. Trends Cell Biol. 2015;25(8):545–55. doi:10.1016/j.tcb.2015.06.002.

49. Varma S, Lal BK, Zheng R, Breslin JW, Saito S, Pappas PJ, et al. Hyperglycemia alters PI3 k and Akt signaling and leads to endothelial cell proliferative dysfunction. Am J Physiol Heart Circ Physiol. 2005;289(4):H1744–51. doi:10.1152/ajpheart.01088.2004.

50. Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes. 2007;56(1):127–36. doi:10.2337/db06-0907.

51. Huang C, Yitzhaki S, Perry CN, Liu W, Giricz Z, Mentzer RM Jr, et al. Autophagy induced by ischemic preconditioning is essential for cardioprotection. J Cardiovasc Transl Res. 2010;3(4):365–73. doi:10.1007/s12265-010-9189-3.

52. Giricz Z, Mentzer RM Jr, Gottlieb RA. Autophagy, myocardial protection, and the metabolic syndrome. J Cardiovasc Pharmacol. 2012;60(2):125–32. doi:10.1097/FJC.0b013e318256ce10.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit